Search & fact check with cited sources for What is GCAR1, a first in class CAR T therapy developed by researchers at the University of Calgary and McMaster University, how does it target solid tumors via the GPNMB protein, what early clinical results has it shown in patients with

What is GCAR1?

GCAR1 is a first-in-class, second-generation chimeric antigen receptor (CAR) T-cell therapy developed by researchers at the University of Calgary and McMaster University, designed specifically to treat solid tumors . It is described as a first-of-its-kind, made-in-Canada discovery for solid cancers .

How it targets solid tumors via GPNMB

GCAR1 targets the GPNMB (glycoprotein non-metastatic melanoma protein B) surface protein, a type I transmembrane glycoprotein regulated by the MiTF transcription factor family . The therapy consists of a patient's own (autologous) T cells that are genetically modified with a lentiviral vector to express a CAR containing a fully human single-chain variable fragment (scFv) binding domain derived from a GPNMB-specific monoclonal antibody .

GPNMB is highly expressed in alveolar soft part sarcoma (ASPS) and other MiT/TFE fusion-driven cancers, as well as in subsets of renal cell carcinoma (RCC), triple-negative breast cancer (TNBC), undifferentiated pleomorphic sarcoma (UPS), and glioblastoma (GBM) . This makes it a clinically tested, safety-proven immunotherapy target .

Early clinical results in alveolar soft part sarcoma (ASPS)

• The first-in-human trial was completed in 2023 .
• Two patients have been treated so far in the clinical trial at the Arthur J.E. Child Comprehensive Cancer Centre in Calgary .
• One patient's life was extended by 18 months before they ultimately passed away from their cancer .
• The second patient experienced significant tumor shrinkage and continues to respond to treatment .
• Researchers report GCAR1 is the first therapy of its kind to show strong promise in treating ASPS .

Important caveat: These results come from a very small number of patients (n=2) and were reported in news coverage rather than a peer-reviewed publication. The rigorous Phase I data have not yet been published in a medical journal.

Additional cancers being tested in the ongoing Phase I/II trial

The current Phase I study (NCT07297667, starting March 2026) is enrolling patients with relapsed/refractory GPNMB-expressing solid tumors, specifically :

• Alveolar soft part sarcoma (ASPS) – the lead indication
• Renal cell carcinoma (excluding clear cell subtype)
• Triple-negative breast cancer (TNBC)

A separate dedicated trial for relapsed ASPS (NCT06813417) is also active .

Why solid tumors are a persistent challenge for CAR-T therapy

CAR-T therapy has been highly successful in blood cancers (like leukemia and lymphoma), but solid tumors pose several major obstacles :

• Immunosuppressive tumor microenvironment (TME): Solid tumors create a hostile environment that actively dampens CAR-T cell function through regulatory T cells, myeloid-derived suppressor cells, and inhibitory cytokines .
• Poor trafficking and infiltration: CAR-T cells struggle to migrate into and penetrate dense solid tumor tissue .
• Antigen heterogeneity and loss: Solid tumors often have mixed antigen expression, allowing antigen-negative cancer cells to escape and cause relapse .
• Lack of truly tumor-specific antigens: Many targets are also expressed on normal tissues, raising the risk of on-target, off-tumor toxicity .
• Physical barriers: Desmoplastic stroma, abnormal vascularization, hypoxia, and altered nutrient availability all impede CAR-T cell access and persistence .

GCAR1's targeting of GPNMB aims to overcome the antigen-specificity challenge, and its early results suggest it is managing some of these hurdles in at least a subset of patients.